Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8494420 | 0.89 | F10 (0.46) | MIFHTTF10NPC1RAB9A | |
| SCHEMBL20645838 | 0.87 | MIF (0.50) | MIFHTTCA1CA2NPC1 | |
| SCHEMBL12461336 | 0.86 | CYP4F2 (0.36) | MIFHTTF10CA1CA2 | |
| SCHEMBL10757347 | 0.84 | MIF (0.46) | MIFHTT | |
| SCHEMBL27526456 | 0.80 | HTT (0.48) | MIFHTTCA1CA2NPC1 | |
| SCHEMBL4664839 | 0.80 | F10 (0.40) | HTTF10CA1CA2NPC1 | |
| SCHEMBL10758499 | 0.80 | MIF (0.42) | MIFHTTCYP1A2CYP2C19CYP2D6 | |
| SCHEMBL20640544 | 0.79 | MIF (0.50) | MIFHTTCA1CA2NPC1 | |
| SCHEMBL20640879 | 0.77 | MIF (0.40) | MIFHTTF10CYP1A2CYP2C19 | |
| SCHEMBL8444142 | 0.74 | MIF (0.58) | MIFHTTCYP1A2CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4397309-A2 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3652178-B1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | GENENTECH, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20210139504-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-10975095-B2 | — | — | 2021-04-13 | — | — | US | disclosed |
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| WO-2019012063-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190100530-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | MIF 2901/4885HTT 2863/4885F10 1951/4885 |
| US-20210139504-A1 | BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF | HSD17B7, CYP11B1, CYP11B2 | MIF 2901/4885HTT 2863/4885F10 1951/4885 |
| US-10975095-B2 | — | CYP1B1, UGT1A1, CYP4B1 | MIF 3173/4885HTT 2124/4885F10 1169/4885 |
| US-11834461-B2 | Bicyclic ketone compounds and methods of use thereof | HSD17B7, CYP11B1, CYP11B2 | MIF 2901/4885HTT 2863/4885F10 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.